PATENT CLAIM ANALYSIS

Application Number: 16162459
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "256000"]

Abstract:
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X 1 , X 2 , X 3 , X 4 , X 5 , Y 1 , Y 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12  and R 13  are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Claim (Index 18):
The method of  claim 17  wherein the at least one cell is a colon cancer cell, a gastric cancer cell, a thyroid cancer cell, a lung cancer cell, a leukemia cell, a B-cell lymphoma, a T-cell lymphoma, a hairy cell lymphoma, Hodgkin's lymphoma cell, non-Hodgkin's lymphoma cell, Burkitt's lymphoma cell, a pancreatic cancer cell, a melanoma cell, a multiple melanoma cell, a brain cancer cell, a CNS cancer cell, a renal cancer cell, a prostate cancer cell, an ovarian cancer cell, or a breast cancer cell.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 97.0
- Lexical Diversity: 2.07576
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15337184', '14426369', '13420988', '13745734', '15355271']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7912052447055444
- 35 USC 102 Novelty (BERT): 0.5339539721675008
- Combined Prediction Score: 0.7654801174517402
- Mean Citation Score: 324.329874
- Max Citation Score: 346.22852
- Similarity Product: 314.4398185111928

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test